QUALIFYING CONDITIONS
Chronic Pain & Medical Marijuana: Pennsylvania & West Virginia Qualifying Condition Guide
Compassionate Certification Centers serves chronic pain patients across Pennsylvania and West Virginia with compassionate, judgment-free evaluations. Whether you’re managing back pain, neuropathy, migraines, fibromyalgia, or another chronic pain condition, our certified physicians are here to help guide your care.
ABOUT CHRONIC PAIN
Chronic pain is one of the most common reasons patients seek medical marijuana certification, and severe chronic or intractable pain is recognized as a qualifying condition in both Pennsylvania and West Virginia. According to the Centers for Disease Control and Prevention, approximately 50 million American adults live with chronic pain. If persistent pain is affecting your daily life, Compassionate Certification Centers can help you understand your options and determine whether a medical marijuana card may be appropriate as part of your pain management plan.
Chronic pain is a complex condition, distinct from the acute pain associated with an injury or short-term illness. It demands ongoing clinical attention and can affect every aspect of a person’s life including physical, emotional, and social. As resistance and risks associated with long-term opioid use have become better understood, interest in medical cannabis as a complementary option for chronic pain management has grown substantially.
What Is Chronic Pain? Definition & Causes
Chronic pain is generally defined as pain that persists for longer than three to six months and continuing even after the underlying injury or illness has healed, or in some cases with no clearly identifiable cause at all. It is a complex sensory and emotional experience that varies significantly between individuals depending on the underlying condition, pain pathway involved, and psychological factors.
Acute Pain vs. Chronic Pain
Acute pain is typically sharp, has a clear underlying cause (such as an injury or surgery), and resolves within days to a few months as the body heals. Chronic pain, by contrast, persists beyond the normal healing timeframe, generally three to six months and may continue indefinitely, sometimes independent of any ongoing tissue damage.
Common Causes of Chronic Pain
Chronic pain can stem from a wide range of underlying conditions, including:
- Injuries that fail to heal properly, leading to persistent nerve sensitization
- Arthritis and other degenerative joint conditions
- Nerve damage (neuropathy) from diabetes, chemotherapy, surgery, or trauma
- Fibromyalgia and other central sensitization disorders
- Endometriosis and chronic pelvic conditions
- Inflammatory Bowel Disease (IBD)
- Chronic Fatigue Syndrome
- Migraine and chronic headache disorders
- Failed back surgery syndrome and chronic post-surgical pain
- Cancer and cancer treatment-related pain
Chronic Pain Conditions That Qualify in Pennsylvania & West Virginia
Both Pennsylvania and West Virginia recognize severe chronic or intractable pain broadly as a qualifying condition. The following specific pain presentations and diagnoses commonly qualify:
- Chronic Back Pain / Chronic Spinal Pain
- Chronic Neck Pain
- Chronic Joint Pain
- Chronic Headaches / Migraine
- Chronic Neuromuscular Pain / Chronic Myalgia / Chronic Myofascial Pain
- Chronic Pelvic Pain
- Chronic Abdominal Pain / Chronic Gastric Pain
- Chronic Pain Due to Cancer or Malignancy
- Chronic Pain Due to Trauma
- Chronic Pain Due to Device, Implant, or Graft
- Chronic Postoperative Pain
- Chronic Pain From Prosthetics
- Chronic Renal Colic / Chronic Kidney Pain
- Chronic Menstrual Pain
- Chronic Limb, Arm, or Foot Pain
- Chronic Face, Jaw, or Throat Pain
- Chronic Bladder, Genital, or Sexual Organ Dysfunction Pain
- Chronic Thoracic, Coronary, or Breast Pain
- Chronic Ear or Eye Pain
This list reflects the breadth of chronic pain presentations that may qualify but is not exhaustive. If you’re unsure whether your specific diagnosis qualifies, our team can review your medical records and help determine eligibility.
How Chronic Pain Presents
Chronic pain can manifest very differently depending on its cause and location. Common presentations include:
- Sharp, dull, burning, or aching sensations that may be constant or intermittent
- Recurrent or persistent headaches and migraines
- Lower back and spinal pain
- Nerve pain, numbness, tingling, burning, or shooting sensations
- Post-surgical pain that persists beyond normal healing time
- Post-traumatic pain following injury
- Psychogenic pain, pain influenced or worsened by psychological factors such as stress, anxiety, or depression
- Fatigue and sleep disturbance secondary to ongoing pain
- Reduced mobility and physical function
- Mood changes, including depression and irritability, related to living with chronic pain
Medical Cannabis & Chronic Pain: What the Research Currently Shows
Cannabis and chronic pain are one of the most studied areas in medical cannabis research and also one of the most contested. Major medical and scientific bodies have reached different conclusions based on the same body of evidence, reflecting genuine scientific uncertainty rather than a settled consensus. This section presents that research honestly, including where expert bodies disagree. It is informational only and does not constitute medical advice.
1. The Evidence Is Real but Modest — and Experts Disagree on Its Significance
A 2021 systematic review and meta-analysis published in The BMJ, pooling 32 randomized controlled trials and 5,174 patients, found that medical cannabis and cannabinoids produced a small improvement in chronic pain, physical functioning, and sleep quality compared to placebo, but the effect sizes were modest. The accompanying BMJ Rapid Recommendation panel issued a weak (conditional) recommendation to offer a trial of non-inhaled medical cannabis for patients whose chronic pain was not adequately controlled by standard care.
Notably, expert bodies have reached different conclusions reviewing similar evidence. The UK’s National Institute for Health and Care Excellence (NICE) issued a 2019 guideline recommending against cannabis for chronic pain, and the International Association for the Study of Pain (IASP) released a 2021 position statement against recommending cannabinoids for pain due to insufficient evidence. By contrast, the European Pain Federation has stated that cannabis-based medicines may be considered by experienced physicians when first- and second-line therapies are insufficient. This divergence reflects genuine, ongoing scientific debate — not a clear-cut answer.
2. Cannabis vs. Opioids: An Important but Limited Comparison
A 2023 systematic review and network meta-analysis published in BMJ Medicine compared medical cannabis directly against opioids for chronic non-cancer pain. The review found that both interventions showed modest pain-relieving effects compared to placebo, with no clear evidence that one was superior to the other for pain control, though the certainty of evidence for both was rated low to very low.
3. Cannabis & Opioid Dosage Reduction: Promising Data With Significant Caveats
A frequently cited 2020 systematic review (Okusanya et al., published in Systematic Reviews) pooled nine studies covering 7,222 chronic pain patients and found that, among patients who used medical cannabis alongside opioids, mean opioid dosage reductions of 64–75% were reported, with 32–59% of patients reporting cannabis substitution for opioids to some degree. These are meaningful findings, but the included studies were observational rather than randomized, meaning they show association rather than proof that cannabis caused the reduction.
This finding should be weighed against more skeptical assessments. A 2022 study published in Frontiers in Pain Research concluded that, by typical scientific standards, the overall evidence on how cannabis affects opioid use “is weak and cannot support routine use of cannabis… for decreasing dose of opioids,” and cautioned that media coverage has outpaced the underlying science. A 2023 study in JAMA Network Open similarly found mixed results when examining real-world opioid dosage changes among New York medical cannabis patients. Patients interested in using cannabis to support an opioid tapering plan should do so collaboratively with their prescribing physician — cannabis should never be used to unilaterally stop or reduce a prescribed opioid regimen without medical guidance.
4. Neuropathic Pain: An Area of Particular Research Interest
Neuropathic pain (nerve-related pain) is among the chronic pain types most frequently studied in cannabis research, and several of the trials included in the 2021 BMJ meta-analysis specifically examined neuropathic pain populations. Results suggest modest benefit similar to other chronic pain types, though as with the broader evidence base, effect sizes are small and most trials are relatively short in duration (typically under 12 weeks).
5. An Updated 2025 Review: Where the Science Stands Now
A 2025 updated systematic review published in Annals of Internal Medicine reaffirmed that cannabis-based products show small-to-modest benefits for chronic pain relative to placebo, consistent with earlier findings, while emphasizing that most trials remain short-term, use varied formulations and dosing, and that more rigorous, longer-duration research is still needed to clarify optimal use, patient selection, and long-term safety.
Medical Disclaimer: The information in this section is provided for general informational purposes only and does not constitute medical advice. Medical cannabis has not been approved by the FDA to treat, cure, or prevent ASD or any of its symptoms. Research in this area is preliminary, and the evidence base — particularly for pediatric populations — is still developing. Always consult your child’s neurologist, developmental pediatrician, and a certified medical marijuana physician before making any changes to a treatment plan.
APPLICATION GUIDE
How to Get a Medical Marijuana Card for Chronic Pain in Pennsylvania or West Virginia
Both Pennsylvania and West Virginia recognize severe chronic or intractable pain as a qualifying condition. The certification process with Compassionate Certification Centers is straightforward:
- Step 1: Register over the phone or online, next-day appointments are often available.
- Step 2: Meet with a certified medical marijuana physician who will review your pain diagnosis, treatment history, and current medications to determine whether certification is appropriate.
- Step 3: Receive your medical marijuana card and begin purchasing from licensed dispensaries in Pennsylvania or West Virginia.
Our physicians are experienced in working collaboratively with pain management specialists and can help ensure that any cannabis-based approach is considered within the full context of your existing treatment plan, including a review of your current medications.
SOURCES & REFERENCES
The following peer-reviewed publications, systematic reviews, and clinical guidelines informed the research summary above. All sources are publicly accessible via PubMed, PMC, or the originating journal. No source should be interpreted as establishing medical cannabis as a guaranteed or first-line treatment for chronic pain.
Foundational Systematic Reviews & Meta-Analyses
[1] Wang L, Hong PJ, May C, et al. (2021). “Medical cannabis or cannabinoids for chronic non-cancer and cancer related pain: a systematic review and meta-analysis of randomised clinical trials.” The BMJ, 374, n1034. PubMed ID: 34497047.
https://pubmed.ncbi.nlm.nih.gov/34497047/
The largest and most rigorous meta-analysis in this field: 32 RCTs, 5,174 patients. Found small but statistically significant improvements in pain, physical function, and sleep quality versus placebo. Authors note effect sizes were modest and most trials were short-term.
[2] BMJ Rapid Recommendations. (2021). “Medical cannabis or cannabinoids for chronic pain: a clinical practice guideline.” The BMJ, 374, n2040.
https://doi.org/10.1136/bmj.n2040
The companion clinical guideline to the Wang et al. meta-analysis. Issued a weak (conditional) recommendation to offer a trial of non-inhaled medical cannabis to patients with chronic pain not adequately controlled by standard therapies — emphasizing this is a conditional, not strong, recommendation.
Differing Expert Conclusions — Important Context
[3] National Institute for Health and Care Excellence (NICE). (2019). “Cannabis-based medicinal products.” NICE Guideline NG144.
https://www.nice.org.uk/guidance/ng144
The UK’s national health guidance body recommended against the routine use of cannabis-based products for chronic pain, citing insufficient evidence of clinical and cost-effectiveness. Included here to represent the genuine divergence of expert opinion on this topic.
[4] International Association for the Study of Pain (IASP). (2021). “IASP Presidential Task Force on Cannabis and Cannabinoid Analgesia: Position Statement.” PAIN, 162(10), S1-S2.
A position statement from the leading international pain research organization concluding there was insufficient evidence to recommend cannabinoids for the management of any pain condition, while acknowledging patient interest and calling for further high-quality research.
Cannabis vs. Opioids & Opioid-Sparing Effects
[5] Busse JW, et al. (2024). “Cannabis for medical use versus opioids for chronic non-cancer pain: a systematic review and network meta-analysis of randomised clinical trials.” BMJ Medicine, 3, e000812. PMC ID: PMC10773353.
https://pmc.ncbi.nlm.nih.gov/articles/PMC10773353/
A network meta-analysis directly comparing cannabis and opioids for chronic non-cancer pain. Found modest benefit from both versus placebo, with no clear evidence either was superior, and low to very low certainty of evidence overall.
[6] Okusanya BO, Asaolu IO, Ehiri JE, et al. (2020). “Medical cannabis for the reduction of opioid dosage in the treatment of non-cancer chronic pain: a systematic review.” Systematic Reviews, 9, 167. PMC ID: PMC7388229.
https://pmc.ncbi.nlm.nih.gov/articles/PMC7388229/
A systematic review of 9 studies (7,222 patients) finding 64–75% mean opioid dosage reductions among patients combining medical cannabis with opioid therapy. This is the source of the original opioid-reduction figures on this page; it is an observational evidence base, not randomized trial data, and shows association rather than proven causation.
[7] Salmasi V, Nelson LM, Hong J, Mackey SC. (2022). “Association of cannabis and/or opioid with quality of life and healthcare utilization in patients with chronic pain.” Frontiers in Pain Research, 3, 1015605.
https://doi.org/10.3389/fpain.2022.1015605
An important counterpoint study concluding that, by normal scientific standards, current evidence on cannabis and opioid use “is weak and cannot support routine use of cannabis in treating chronic pain or its effect in decreasing dose of opioids,” and cautions that media coverage of this topic has outpaced the underlying science.
[8] Nguyen T, Li Y, Greene D, Stancliff S, Quackenbush N. (2023). “Changes in Prescribed Opioid Dosages Among Patients Receiving Medical Cannabis for Chronic Pain, New York State, 2017–2019.” JAMA Network Open, 6(1), e2254573. PubMed ID: 36716026.
https://pubmed.ncbi.nlm.nih.gov/36716026/
A real-world New York State cohort study examining opioid prescription changes among medical cannabis patients. Findings were more modest and mixed than earlier observational studies, illustrating how results vary across study populations and designs.
Most Recent Evidence (2025)
[9] (2025). “Cannabis-Based Products for Chronic Pain: An Updated Systematic Review.” Annals of Internal Medicine, 179(2). https://www.acpjournals.org/doi/10.7326/ANNALS-25-03152
The most recent major systematic review in this field, updating earlier evidence with newer trials through late 2025. Reaffirms small-to-modest benefit for chronic pain relative to placebo, consistent with the 2021 BMJ findings, and continues to call for longer, more rigorous trials to clarify optimal patient selection and dosing.
